Biogen: all 548 studies

Page 2 of 6. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).TerminatedNCT02462759Phase 2Results posted
• Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMDCompletedNCT02461771Phase 1Results posted
• Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)CompletedNCT02443740Phase 1Results posted
• BG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisTerminatedNCT02430532Phase 3Results posted
• Tecfidera Slow-Titration StudyTerminatedNCT02428231Phase 3Results posted
• Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving TecfideraCompletedNCT02410278Phase 4Results posted
• Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMSCompletedNCT02410200Phase 2Results posted
• A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular AtrophyCompletedNCT02386553Phase 2Results posted
• Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.TerminatedNCT02343159Phase 4Results posted
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsTerminatedNCT02342704Phase 4Results posted
• A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy SubjectsCompletedNCT02341482Phase 1Results posted
• Multiple Ascending Doses of PF-04958242 in Subjects With Stable SchizophreniaCompletedNCT02332798Phase 1Results posted
• A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)CompletedNCT02292537Phase 3Results posted
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT02283853Phase 3Results posted
• A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNHCompletedNCT02264639Phase 1Results posted
• RTA 408 Capsules in Patients With Melanoma - REVEALCompletedNCT02259231Phase 1/2Results posted
• A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's AtaxiaCompletedNCT02255435Phase 2Results posted
• RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTORCompletedNCT02255422Phase 2Results posted
• Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other TherapiesTerminatedNCT02241785Phase 4Results posted
• Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy VolunteersCompletedNCT02228395Phase 1Results posted
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple SclerosisCompletedNCT02219932Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular AtrophyTerminatedNCT02193074Phase 3Results posted
• RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSECompletedNCT02142959Phase 2Results posted
• RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARDCompletedNCT02128113Phase 2Results posted
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In GermanyCompletedNCT02125604Phase 4Results posted
• Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.CompletedNCT02097849Phase 2Results posted
• Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT02090413Phase 4Results posted
• RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular SurgeryCompletedNCT02065375Phase 2Results posted
• Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATCompletedNCT02036970Phase 2Results posted
• Effect of Natalizumab on Infarct Volume in Acute Ischemic StrokeCompletedNCT01955707Phase 2Results posted
• Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)CompletedNCT01939002Phase 3Results posted
• BIIB023 Long-Term Extension Study in Subjects With Lupus NephritisTerminatedNCT01930890Phase 2Results posted
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United StatesCompletedNCT01873417Phase 4Results posted
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With AvonexCompletedNCT01864148Phase 2Results posted
• A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)CompletedNCT01839656Phase 2Results posted
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019TerminatedNCT01797965Phase 3Results posted
• BIIB033 In Acute Optic Neuritis (AON)CompletedNCT01721161Phase 2Results posted
• An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular AtrophyCompletedNCT01703988Phase 1/2Results posted
• Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl FumarateCompletedNCT01568112Phase 3Results posted
• BIIB023 Proof-of-Concept Study in Participants With Lupus NephritisTerminatedNCT01499355Phase 2Results posted
• Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple SclerosisCompletedNCT01480076Phase 4Results posted
• An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisCompletedNCT01462318Phase 3Results posted
• Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT01440101Phase 2/3Results posted
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisTerminatedNCT01416181Phase 3Results posted
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01416155Phase 2Results posted
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)CompletedNCT01405820Phase 2Results posted
• STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01371305Phase 2Results posted
• Long-Term Safety and Efficacy Study of Peginterferon Beta-1aCompletedNCT01332019Phase 3Results posted
• Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)TerminatedNCT01211665Phase 4Results posted
• BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisCompletedNCT01156311Phase 2Results posted
• Treatment Interruption of NatalizumabCompletedNCT01071083Phase 2Results posted
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01064401Phase 3Results posted
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedNCT01058005Phase 3Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT01051349Phase 2Results posted
• Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisCompletedNCT00906399Phase 3Results posted
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00871780Phase 4Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00870740Phase 2Results posted
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)CompletedNCT00835770Phase 3Results posted
• Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis SubjectsCompletedNCT00828204Phase 3Results posted
• Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) PatientsTerminatedNCT00784836Phase 3Results posted
• Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)TerminatedNCT00746941Phase 1/2Results posted
• Study of Natalizumab in Relapsed/Refractory Multiple MyelomaTerminatedNCT00675428Phase 1/2Results posted
• A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative ColitisCompletedNCT00616434Phase 2Results posted
• The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple SclerosisCompletedNCT00536120Phase 4Results posted
• Natalizumab High Titer Immunogenicity and SafetyCompletedNCT00516893Phase 2Results posted
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisCompletedNCT00451451Phase 3Results posted
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisCompletedNCT00420212Phase 3Results posted
• Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00390221Phase 2Results posted
• Natalizumab Re-Initiation of DosingCompletedNCT00306592Phase 3Results posted
• Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid ArthritisTerminatedNCT00298272Phase 2Results posted
• Natalizumab (Tysabri) Re-Initiation of DosingTerminatedNCT00297232Phase 3Results posted
• Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving MethotrexateTerminatedNCT00083759Phase 2Results posted
• A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55CompletedNCT07297199Phase 1
• A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)Active, not recruitingNCT07223723Phase 4
• Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled SyringeCompletedNCT07214740Phase 3
• A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55CompletedNCT07149415Phase 1
• A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their PregnancyCompletedNCT07047820
• Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft TransplantationWithdrawnNCT07020832Phase 3
• A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55CompletedNCT07019064Phase 1
• A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's AtaxiaActive, not recruitingNCT06953583Phase 3
• A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different WaysCompletedNCT06741657Phase 1
• A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)Active, not recruitingNCT06685757Phase 3
• A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy ParticipantsCompletedNCT06640933Phase 1
• A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping MilkCompletedNCT06612879Phase 1
• A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy ParticipantsCompletedNCT06574828Phase 1
• Geographic Atrophy Long-Terms Outcomes StudyCompletedNCT06499571
• A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy AdultsCompletedNCT06454721Phase 1
• A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male ParticipantsCompletedNCT06311786Phase 1
• A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy ParticipantsCompletedNCT06264440Phase 1
• A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationActive, not recruitingNCT06161584
• A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) TreatmentsCompletedNCT06127095
• A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldCompletedNCT06064929Phase 1
• A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years OldActive, not recruitingNCT06054893Phase 1
• A Study of Safety and Drug Levels of HIB210 in Healthy VolunteersCompletedNCT05928585Phase 1
• A TQTc Study for OmaveloxoloneCompletedNCT05927649Phase 1
• A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)Active, not recruitingNCT05925049
• An Open-label DDI Study of Omaveloxolone in Healthy SubjectsCompletedNCT05909644Phase 1
• An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisActive, not recruitingNCT05809531Phase 3
• A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)CompletedNCT05798520Phase 2
• A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)Active, not recruitingNCT05767736

← Biogen overview and focus areas